Entrada Therapeutics Inc. (TRDA) Insider Trading

Last 12 months

Insiders bought $29k and sold $4.9M on the open market.

26% of the selling was scheduled in advance under 10b5-1 plans. Director Kush Parmar sold $1.76M on Nov 14, 2025 outside a plan.

Net open-market

−$4.87M

1 buy · 10 sales

Under a 10b5-1 plan

26%

of the value sold

Insiders who bought / sold

1 / 4

executives and directors

Last open-market buy

May 2026

May 20, 2026

Get an email when TRDA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 4 – 9	MPM Bioventures 2018 GP LLC Large holder	SoldNo plan 3 parts	259,837	$7.33 average	$1.91M	6.3%	Form 4
Sep 4 – 9	MPM Bioventures 2018 (b), L.p. Large holder	SoldNo plan 3 parts	259,837	$7.33 average	$1.91M	6.3%	Form 4
Sep 1 – 3	MPM Bioventures 2018 LLC Large holder	SoldNo plan 3 parts	86,482	$7.14 average	$617k	2.0%	Form 4
Sep 1 – 3	MPM Bioventures 2014 GP LLC Large holder	SoldNo plan 3 parts	86,482	$7.14 average	$617k	2.0%	Form 4
Aug 27 – 31	MPM Bioventures 2018 LLC Large holder	SoldNo plan 3 parts	86,914	$7.08 average	$616k	2.0%	Form 4
Aug 27 – 31	MPM Bioventures 2014 (b), L.p. Large holder	SoldNo plan 3 parts	86,914	$7.08 average	$616k	2.0%	Form 4
Aug 24 – 26	Todd Foley Large holder	SoldNo plan 3 parts	62,714	$7.36 average	$462k	1.4%	Form 4
Aug 24 – 26	MPM Bioventures 2018 LLC Large holder	SoldNo plan 3 parts	62,714	$7.36 average	$462k	1.4%	Form 4
Aug 6 – 10	Kush Parmar Director	SoldNo plan 3 parts	155,255	$6.95 average	$1.08M	3.9%	Form 4
Aug 6 – 7	Scott M Rocklage Large holder	SoldNo plan 2 parts	62,811	$6.88 average	$432k	1.6%	Form 4
Jul 30 – 31	Kush Parmar Director	SoldNo plan 2 parts	116,474	$6.93 average	$807k	2.9%	Form 4
Jul 30 – 31	Scott M Rocklage Large holder	SoldNo plan 2 parts	116,474	$6.93 average	$807k	2.9%	Form 4
May 20	Bernhardt G Zeiher Director	Bought	5,000	$5.86	$29k	New	Form 4
May 4	Natarajan Sethuraman President, Research & Develop.	Sold10b5-1 plan	25,907	$15.39	$399k	11%	Form 4
May 4	Nathan J Dowden President & COO	Sold10b5-1 plan	15,000	$15.33	$230k	7.0%	Form 4
Apr 1	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan	2,500	$12.95	$32k	2.1%	Form 4
Mar 9 – 10	Nathan J Dowden President & COO	Sold10b5-1 plan 2 parts	15,010	$13.04 average	$196k	7.0%	Form 4
Mar 9 – 10	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan 2 parts	16,477	$13.01 average	$214k	12%	Form 4
Mar 4	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan	7,988	$12.25	$98k	5.5%	Form 4
Nov 21, 2025	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan	8,910	$9.98	$89k	7.5%	Form 4
Nov 20, 2025	Felix Baker Large holder	Bought 4 parts	28,867	$9.07 average	$262k	0.6%	Form 4
Nov 14, 2025	Kush Parmar Director	SoldNo plan	200,000	$8.80	$1.76M	4.7%	Form 4
Nov 14, 2025	5AM Ventures V, L.p. Large holder	SoldNo plan	200,000	$8.80	$1.76M	4.7%	Form 4
Nov 10, 2025 – Nov 12, 2025	Baker Bros. Advisors (gp) LLC Large holder	Bought 12 parts	178,044	$7.60 average	$1.35M	4.0%	Form 4
Jul 9, 2025	Kush Parmar Director	SoldNo plan 2 parts	27,000	$7.50 average	$203k	0.6%	Form 4
Jul 9, 2025	5AM Opportunities I, L.p. Large holder	SoldNo plan 2 parts	27,000	$7.50 average	$203k	0.6%	Form 4
Jun 27, 2025 – Jul 1, 2025	Kush Parmar Director	SoldNo plan 6 parts	125,000	$6.93 average	$866k	2.8%	Form 4
Jun 27, 2025 – Jul 1, 2025	Andrew J. Schwab Large holder	SoldNo plan 6 parts	125,000	$6.93 average	$866k	2.8%	Form 4
Mar 17, 2025	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan	1,784	$10.67	$19k	1.6%	Form 4
Dec 10, 2024 – Dec 11, 2024	MPM Bioventures 2018 GP LLC Large holder	SoldNo plan 2 parts	44,722	$20.51 average	$917k	1.0%	Form 4
Dec 10, 2024 – Dec 11, 2024	MPM Asset Management Investors Bv2018 LLC Large holder	SoldNo plan 2 parts	44,722	$20.51 average	$917k	1.0%	Form 4
Nov 29, 2024 – Dec 3, 2024	Natarajan Sethuraman President, Research & Develop.	Sold10b5-1 plan 3 parts	15,891	$20.18 average	$321k	9.9%	Form 4
Nov 29, 2024 – Dec 2, 2024	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan 2 parts	6,000	$20.00 average	$120k	7.5%	Form 4
Nov 11, 2024 – Nov 13, 2024	Natarajan Sethuraman President, Research & Develop.	Sold10b5-1 plan 2 parts	4,109	$20.03 average	$82k	2.5%	Form 4
Nov 11, 2024	Kory James Wentworth Chief Financial Officer	Sold10b5-1 plan	8,637	$19.98	$173k	10%	Form 4
Nov 4, 2024 – Nov 6, 2024	Natarajan Sethuraman President, Research & Develop.	Sold10b5-1 plan 4 parts	18,219	$18.62 average	$339k	9.9%	Form 4

Sep 4 – 9No plan
MPM Bioventures 2018 GP LLC
Large holder · sold 259,837 at avg $7.33
$1.91M
6.3% of stake
Sep 4 – 9No plan
MPM Bioventures 2018 (b), L.p.
Large holder · sold 259,837 at avg $7.33
$1.91M
6.3% of stake
Sep 1 – 3No plan
MPM Bioventures 2018 LLC
Large holder · sold 86,482 at avg $7.14
$617k
2.0% of stake
Sep 1 – 3No plan
MPM Bioventures 2014 GP LLC
Large holder · sold 86,482 at avg $7.14
$617k
2.0% of stake
Aug 27 – 31No plan
MPM Bioventures 2018 LLC
Large holder · sold 86,914 at avg $7.08
$616k
2.0% of stake
Aug 27 – 31No plan
MPM Bioventures 2014 (b), L.p.
Large holder · sold 86,914 at avg $7.08
$616k
2.0% of stake
Aug 24 – 26No plan
Todd Foley
Large holder · sold 62,714 at avg $7.36
$462k
1.4% of stake
Aug 24 – 26No plan
MPM Bioventures 2018 LLC
Large holder · sold 62,714 at avg $7.36
$462k
1.4% of stake
Aug 6 – 10No plan
Kush Parmar
Director · sold 155,255 at avg $6.95
$1.08M
3.9% of stake
Aug 6 – 7No plan
Scott M Rocklage
Large holder · sold 62,811 at avg $6.88
$432k
1.6% of stake
Jul 30 – 31No plan
Kush Parmar
Director · sold 116,474 at avg $6.93
$807k
2.9% of stake
Jul 30 – 31No plan
Scott M Rocklage
Large holder · sold 116,474 at avg $6.93
$807k
2.9% of stake
May 20
Bernhardt G Zeiher
Director · bought 5,000 at $5.86
$29k
New position
May 410b5-1 plan
Natarajan Sethuraman
President, Research & Develop. · sold 25,907 at $15.39
$399k
11% of stake
May 410b5-1 plan
Nathan J Dowden
President & COO · sold 15,000 at $15.33
$230k
7.0% of stake
Apr 110b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 2,500 at $12.95
$32k
2.1% of stake
Mar 9 – 1010b5-1 plan
Nathan J Dowden
President & COO · sold 15,010 at avg $13.04
$196k
7.0% of stake
Mar 9 – 1010b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 16,477 at avg $13.01
$214k
12% of stake
Mar 410b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 7,988 at $12.25
$98k
5.5% of stake
Nov 21, 202510b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 8,910 at $9.98
$89k
7.5% of stake
Nov 20, 2025
Felix Baker
Large holder · bought 28,867 at avg $9.07
$262k
0.6% of stake
Nov 14, 2025No plan
Kush Parmar
Director · sold 200,000 at $8.80
$1.76M
4.7% of stake
Nov 14, 2025No plan
5AM Ventures V, L.p.
Large holder · sold 200,000 at $8.80
$1.76M
4.7% of stake
Nov 10, 2025 – Nov 12, 2025
Baker Bros. Advisors (gp) LLC
Large holder · bought 178,044 at avg $7.60
$1.35M
4.0% of stake
Jul 9, 2025No plan
Kush Parmar
Director · sold 27,000 at avg $7.50
$203k
0.6% of stake
Jul 9, 2025No plan
5AM Opportunities I, L.p.
Large holder · sold 27,000 at avg $7.50
$203k
0.6% of stake
Jun 27, 2025 – Jul 1, 2025No plan
Kush Parmar
Director · sold 125,000 at avg $6.93
$866k
2.8% of stake
Jun 27, 2025 – Jul 1, 2025No plan
Andrew J. Schwab
Large holder · sold 125,000 at avg $6.93
$866k
2.8% of stake
Mar 17, 202510b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 1,784 at $10.67
$19k
1.6% of stake
Dec 10, 2024 – Dec 11, 2024No plan
MPM Bioventures 2018 GP LLC
Large holder · sold 44,722 at avg $20.51
$917k
1.0% of stake
Dec 10, 2024 – Dec 11, 2024No plan
MPM Asset Management Investors Bv2018 LLC
Large holder · sold 44,722 at avg $20.51
$917k
1.0% of stake
Nov 29, 2024 – Dec 3, 202410b5-1 plan
Natarajan Sethuraman
President, Research & Develop. · sold 15,891 at avg $20.18
$321k
9.9% of stake
Nov 29, 2024 – Dec 2, 202410b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 6,000 at avg $20.00
$120k
7.5% of stake
Nov 11, 2024 – Nov 13, 202410b5-1 plan
Natarajan Sethuraman
President, Research & Develop. · sold 4,109 at avg $20.03
$82k
2.5% of stake
Nov 11, 202410b5-1 plan
Kory James Wentworth
Chief Financial Officer · sold 8,637 at $19.98
$173k
10% of stake
Nov 4, 2024 – Nov 6, 202410b5-1 plan
Natarajan Sethuraman
President, Research & Develop. · sold 18,219 at avg $18.62
$339k
9.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TRDA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

BOLTBolt Biotherapeutics Inc.

KYNBKyntra Bio, Inc.

ENSCEnsysce Biosciences Inc.

RANIRani Therapeutics Holdings Inc.

PCYNProcyon Corporation

CAMPCamp4 Therapeutics Corp.

ATAIAtaiBeckley Inc.

CPHIChina Pharma Holdings Inc.

Spot a number that looks wrong? Check it in TRDA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TRDA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.